Celogics
Celogics is a Seattle-based joint venture formed in 2021 by Curi Bio and NEXEL that manufactures and sells human iPSC-derived cardiomyocytes plus a custom iPSC differentiation service for pharmaceutical, academic, and CRO customers in drug discovery and cardiac safety screening.
- Company typePrivate
- Founded2021
- HeadquartersMukilteo, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Celogics does
Celogics Inc. is a Seattle-based private joint venture formed in October 2021 between Curi Bio (US stem cell platform developer) and NEXEL (Korean iPSC pioneer, first Korean company to in-license iPSC technology) to commercialize human induced pluripotent stem cell (iPSC)-derived cell products for drug discovery, drug safety screening, and disease modeling. The company's core product is Celo.Cardiomyocytes, a highly pure and electrophysiologically active population of human iPSC-derived ventricular cardiomyocytes manufactured under proprietary serum-free protocols with Quality-by-Design (QbD) principles, real-time monitoring, and statistical process control. Claimed performance metrics include 100 percent batch reproducibility sustained over four years and standardization across more than 50 distinct iPSC lines, addressing the industry-wide variability problem that drives repeated studies and late-stage failures. Celo.Cardiomyocytes are priced at $1,100 per vial of 5 million cells, with an Advanced Media Kit at $200 and a Complete Culture Kit bundle at $1,300; cell performance is validated across at least five third-party instruments (Curi Bio Mantarray, Axion Maestro, Nanion CardioExcyte96, Nanion Patchliner, ACEA CardioECR).
The company generates revenue through catalog cell and media product sales (one-time purchases) and through the Celogics Suit custom iPSC differentiation service, a three-phase professional services engagement covering iPSC banking, protocol optimization, and custom manufacturing for cardiomyocytes, neurons, hepatocytes, and other cell types, deliverable in as little as nine weeks. The customer base is horizontally segmented across global pharmaceutical companies, academic and research institutions, and contract research organizations, accessed through a B2B enterprise sales motion supported by industry conference presence (SOT, ISSCR, TERMIS-EU, SPS) and an inbound quote-request funnel. Distribution leverages NEXEL's existing network reaching 6,000+ research institutions globally. Operations are led by CEO Jin Hyuk Chang, CBO Rachel Clemens, and CSO Christal Worthen PhD, with a current team of 1-10 employees, ISO 9001-certified quality controls, and a manufacturing and distribution headquarters in Seattle alongside a Mukilteo office supporting the technical sales function.
Celogics firmographics
Firmographics- Name
- Celogics
- Legal name
- Celogics Inc.
- Website
- https://celogics.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Celogics is a Seattle-based joint venture formed in 2021 by Curi Bio and NEXEL that manufactures and sells human iPSC-derived cardiomyocytes plus a custom iPSC differentiation service for pharmaceutical, academic, and CRO customers in drug discovery and cardiac safety screening.
- Ownership category
- akta.pro rank
Where Celogics is headquartered
LocationHeadquarters
- HQ city
- Mukilteo
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Celogics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- iPSC-Derived Cell Products: Sale of Celo.Cardiomyocytes (iPSC-derived ventricular cardiomyocytes) and related media kits. One-time product purchases with optional repeat media kit orders.
- Custom Differentiation Services (Celogics Suit): Custom iPSC differentiation service where Celogics produces specific cell types tailored to customer research needs. Includes iPSC banking, protocol optimization, and manufacturing phases.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Celo.Cardiomyocytes (5x10^6 cells) - $1,100 per vial |
| Unit Pricing | Pay-as-you-go | Advanced Media Kit - $200 |
| Unit Pricing | Pay-as-you-go | Complete Culture Kit - $1,300 |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Celogics product offering
Product offeringCore offering
Celogics manufactures and sells human induced pluripotent stem cell (iPSC)-derived cell products — primarily Celo.Cardiomyocytes (ventricular cardiomyocytes) — and serum-free media kits for use in drug discovery, drug safety screening, and disease modeling. The company also provides custom iPSC differentiation services (Celogics Suit) producing tailored cell types such as neurons and hepatocytes for pharmaceutical companies and academic researchers, leveraging proprietary protocols and Quality-by-Design manufacturing to deliver 100% batch reproducibility across 50+ iPSC lines.
Product overview
Celogics is a Seattle-based joint venture between Curi Bio and NEXEL (formed October 2021) focused on iPSC-derived cell products for drug discovery, drug safety screening, and disease modeling. The core product is Celo.Cardiomyocytes — a highly pure, electrophysiologically active population of human iPSC-derived ventricular cardiomyocytes cultured under serum-free conditions, sold as individual cell vials ($1,100), bundled with serum-free Advanced Media Kit ($200), or as a Complete Culture Kit ($1,300). Supporting the core product, Celogics offers Custom Cardiomyocytes under its Celogics Suit custom differentiation service, which provides precisely differentiated iPSC-derived cells including cardiomyocytes, neurons, and hepatocytes through a three-phase process (iPSC banking, protocol optimization, manufacturing) deliverable in as little as 9 weeks. The portfolio also includes comprehensive Product Literature (User Guide, MEA User Guide, Certificate of Analysis, Product Data Sheet) and the Customized Differentiations service for broader cell type customization.
Differentiator
Problem solved
Functional benefit
Brands
- Celo.Cardiomyocytes: Highly pure and electrophysiologically active population of human iPSC-derived ventricular cardiomyocytes for drug discovery, safety screening, and disease modeling.
- Celo.Cells
- Celogics Suit
Products and services
- Celo.Cardiomyocytes Human iPSC-derived ventricular cardiomyocytes (5x10^6 cells per vial) cultured under serum-free conditions, featuring spontaneous beating, high purity, and electrophysiological activity validated across multiple platforms (Axion Maestro, Nanion CardioExcyte96, Nanion Patchliner, Curi Bio Mantarray, ACEA CardioECR). Designed for pharmaceutical drug discovery, drug safety screening, and disease modeling applications; sold to pharmaceutical companies, academic researchers, and CROs.
- Celogics Suit (Custom iPSC Differentiation Service) Custom iPSC differentiation service delivering tailored cell types (cardiomyocytes, neurons, hepatocytes, and others) from iPSC lines, including genetic modifications. The service runs through a three-phase process — iPSC banking, protocol optimization and QC setup, and custom cell manufacturing — with project tracking via an Electronic Laboratory Notebook (ELN) for transparency. Targeted at pharmaceutical companies and academic researchers needing non-standard cell types or modifications.
- Custom Cardiomyocytes Custom cardiomyocytes engineered to meet unique research and therapeutic requirements using proprietary in-house optimization protocols and cardiac differentiation expertise. Offers reproducible production lots, adaptable QC standards, and tailored delivery in as little as 9 weeks; for pharmaceutical and academic researchers needing project-specific cardiomyocyte specifications.
Quantifiable outcome
- 100% batch reproducibility over 4 years with low variability
- +3 more outcomes
Companies that use Celogics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Celogics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Celogics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Curi BiocoreCelogics is a joint venture between Curi Bio and NEXEL. Curi Bio is a global leader in development of human stem cell-based platforms for disease modeling and drug discovery, with market-leading products including Mantarray 3D engineered tissue platform and ComboMat for advanced functional maturation of iPSC-derived cardiomyocytes. Curi Bio has been awarded more than $7M in NIH grant funding. Celogics provides Curi Bio's iPSC-derived cell products to US markets and will develop next-generation products.
- NEXELcoreNEXEL is a Korean bio-company incorporated in 2012 with proprietary stem cell technologies. They were the first Korean company to in-license iPSC technology and have commercialized Cardiosight-S hiPSC-derived cardiomyocytes, Hepatosight-S, and Neurosight-S. NEXEL provides iPSC technology and product rights to Celogics for US market access. The partnership enables NEXEL's strategic entry into the US market, which accounts for nearly 50% of the global stem cell market.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Celogics competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Customer concentration
Celogics social profiles
Digital presenceCelogics compliance and trust
Trust signalCompliance1 record
Celogics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Celogics leadership team
Management profileNumber of profiles
Profiles7 records
Celogics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Celogics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Celogics
What does Celogics do?
Celogics manufactures and sells human induced pluripotent stem cell (iPSC)-derived cell products — primarily Celo.Cardiomyocytes (ventricular cardiomyocytes) — and serum-free media kits for use in drug discovery, drug safety screening, and disease modeling. The company also provides custom iPSC differentiation services (Celogics Suit) producing tailored cell types such as neurons and hepatocytes for pharmaceutical companies and academic researchers, leveraging proprietary protocols and Quality-by-Design manufacturing to deliver 100% batch reproducibility across 50+ iPSC lines.
Is Celogics a public or private company?
Celogics is a private company. It is classified as corporate owned and is currently operating.
When was Celogics founded?
Celogics was founded in 2021. It employs 1 to 10 people.
Where is Celogics based?
Celogics is headquartered in Mukilteo, United States, in the North America region.
How does Celogics make money?
Two revenue lines are on record. iPSC-Derived Cell Products are the primary driver. The others are custom Differentiation Services (Celogics Suit).
Does Celogics have an API?
No public API is recorded for Celogics.